what planet are you on...its been reported by AP, Bloomberg, Reuters, Forbes......
OPTT's current market value is around $40m. it had $18m as at Oct 31 so lets knock off $15 conservatively to arrive at a enterprise value of about $25m. They have just got $200m + deal and also have existing contract backlog of about $5m. Over the past 15 years the company has expended over $200m in developing its technology so I reckon the technology value is at least worth $50m.
Keeping all this is in mind $25m enterprise value looks dirt cheap. If wave power is finally about to become commercial scale, OPTT will be taken over if its valuation stays around these levels. The intrinsic value of the business, its technology and projects is well above the current price - thatmy gut feeling.
I reckon $5 a share price looks very realistic. its high risk but so are so many biotechs which are on billion dollar values based on some ongoing clinical trials of unproven drugs.
Sentiment: Strong Buy
as I said earlier - i have managed to buy some shares today at $7.59. This is going to $10 at least in the next few days/ months.
they would like but 0% response is unusual and there may be something wrong with results data, the tests were carried out in corrupt countries like India, Ukraine etc.
Money talks, #$%$ walks.if they have confidence in the data, the way to allay concerns expressed by AF or anyone is if all the directors buy shares in the open market now. They gotta put down hard cash on the table.
I own a few shares in CYRX and I believe AF's article was great and raised a lot of good points including how the non executive awarded themselves stock ahead of the news. The SEC needs to probe that alone and there should be a closed period to trade shares etc ahead of such important news.
As a investor I also want to hear what the company has to say about the clinical trial issues raised by AF. Nothing less than a detailed rebuttal will satisfy the market or me. AF is only doing the job that regulators should be doing.
the company may be planning to raise some more cash, which is why the analysts have been holding off saying anything. always happens like that. new money gets raised soon after good clinical tests.